A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer

摘要: BACKGROUND: The current study was conducted to demonstrate the utility of a multiplexed, particle-based flow cytometric assay for simultaneous analysis panel matrix metalloproteinases (MMPs) using small volumes plasma samples from patients with bladder cancer. In addition, authors attempted test hypothesis that levels MMPs are associated time cancer-related death. METHODS: Plasma MMP concentrations (MMP-1, -2, -3, -7, -8, -9, and -12) in 135 presenting high-grade ≥T1 cancer were measured. Data regarding clinical pathologic features ascertained retrospective fashion. RESULTS: The median duration follow-up 30.4 months. At analysis, 61 had died, including 45 (33.3%) who died Plasma MMP-12 not measurable. For all other MMPs, intra-assay coefficient variation varied 6.12% 9.82%. MMP-1, -9 found be significantly death. MMP-7 death after adjustment competing (hazard ratio [HR], 2.2; 95% confidence interval [95% CI], 1.1-4.5 [P = .022]). The 5-year cancer-specific survival rates those above below value (300 pg/mL) 73.6% (95% CI, 60.0-83.2%) 48.0% 32.5-61.9%), respectively (P .01). CONCLUSIONS: Multiplexed, allows high-throughput measurement multiple or serum proteins simultaneously. By this new technology cohort cancer, identified as being Cancer 2010. © 2010 American Society.